TY  - JOUR
A1  - Göbel, Kerstin
A1  - Pankratz, Susann
A1  - Asaridou, Chloi-Magdalini
A1  - Herrmann, Alexander M.
A1  - Bittner, Stefan
A1  - Merker, Monika
A1  - Ruck, Tobias
A1  - Glumm, Sarah
A1  - Langhauser, Friederike
A1  - Kraft, Peter
A1  - Krug, Thorsten F.
A1  - Breuer, Johanna
A1  - Herold, Martin
A1  - Gross, Catharina C.
A1  - Beckmann, Denise
A1  - Korb-Pap, Adelheid
A1  - Schuhmann, Michael K.
A1  - Kuerten, Stefanie
A1  - Mitroulis, Ioannis
A1  - Ruppert, Clemens
A1  - Nolte, Marc W.
A1  - Panousis, Con
A1  - Klotz, Luisa
A1  - Kehrel, Beate
A1  - Korn, Thomas
A1  - Langer, Harald F.
A1  - Pap, Thomas
A1  - Nieswandt, Bernhard
A1  - Wiendl, Heinz
A1  - Chavakis, Triantafyllos
A1  - Kleinschnitz, Christoph
A1  - Meuth, Sven G.
T1  - Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells
JF  - Nature Communications
N2  - Aberrant immune responses represent the underlying cause of central nervous system (CNS) autoimmunity, including multiple sclerosis (MS). Recent evidence implicated the crosstalk between coagulation and immunity in CNS autoimmunity. Here we identify coagulation factor XII (FXII), the initiator of the intrinsic coagulation cascade and the kallikrein–kinin system, as a specific immune cell modulator. High levels of FXII activity are present in the plasma of MS patients during relapse. Deficiency or pharmacologic blockade of FXII renders mice less susceptible to experimental autoimmune encephalomyelitis (a model of MS) and is accompanied by reduced numbers of interleukin-17A-producing T cells. Immune activation by FXII is mediated by dendritic cells in a CD87-dependent manner and involves alterations in intracellular cyclic AMP formation. Our study demonstrates that a member of the plasmatic coagulation cascade is a key mediator of autoimmunity. FXII inhibition may provide a strategy to combat MS and other immune-related disorders.
KW  - blood coagulation
KW  - factor XII
KW  - neuroinflammation
KW  - dendric cells
Y1  - 2016
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-165503
VL  - 7
IS  - 11626
ER  - 
TY  - JOUR
A1  - Breuer, René
A1  - Mattheisen, Manuel
A1  - Frank, Josef
A1  - Krumm, Bertram
A1  - Treutlein, Jens
A1  - Kassem, Layla
A1  - Strohmaier, Jana
A1  - Herms, Stefan
A1  - Mühleisen, Thomas W.
A1  - Degenhardt, Franziska
A1  - Cichon, Sven
A1  - Nöthen, Markus M.
A1  - Karypis, George
A1  - Kelsoe, John
A1  - Greenwood, Tiffany
A1  - Nievergelt, Caroline
A1  - Shilling, Paul
A1  - Shekhtman, Tatyana
A1  - Edenberg, Howard
A1  - Craig, David
A1  - Szelinger, Szabolcs
A1  - Nurnberger, John
A1  - Gershon, Elliot
A1  - Alliey-Rodriguez, Ney
A1  - Zandi, Peter
A1  - Goes, Fernando
A1  - Schork, Nicholas
A1  - Smith, Erin
A1  - Koller, Daniel
A1  - Zhang, Peng
A1  - Badner, Judith
A1  - Berrettini, Wade
A1  - Bloss, Cinnamon
A1  - Byerley, William
A1  - Coryell, William
A1  - Foroud, Tatiana
A1  - Guo, Yirin
A1  - Hipolito, Maria
A1  - Keating, Brendan
A1  - Lawson, William
A1  - Liu, Chunyu
A1  - Mahon, Pamela
A1  - McInnis, Melvin
A1  - Murray, Sarah
A1  - Nwulia, Evaristus
A1  - Potash, James
A1  - Rice, John
A1  - Scheftner, William
A1  - Zöllner, Sebastian
A1  - McMahon, Francis J.
A1  - Rietschel, Marcella
A1  - Schulze, Thomas G.
T1  - Detecting significant genotype–phenotype association rules in bipolar disorder: market research meets complex genetics
JF  - International Journal of Bipolar Disorders
N2  - Background
Disentangling the etiology of common, complex diseases is a major challenge in genetic research. For bipolar disorder (BD), several genome-wide association studies (GWAS) have been performed. Similar to other complex disorders, major breakthroughs in explaining the high heritability of BD through GWAS have remained elusive. To overcome this dilemma, genetic research into BD, has embraced a variety of strategies such as the formation of large consortia to increase sample size and sequencing approaches. Here we advocate a complementary approach making use of already existing GWAS data: a novel data mining procedure to identify yet undetected genotype–phenotype relationships. We adapted association rule mining, a data mining technique traditionally used in retail market research, to identify frequent and characteristic genotype patterns showing strong associations to phenotype clusters. We applied this strategy to three independent GWAS datasets from 2835 phenotypically characterized patients with BD. In a discovery step, 20,882 candidate association rules were extracted.

Results
Two of these rules—one associated with eating disorder and the other with anxiety—remained significant in an independent dataset after robust correction for multiple testing. Both showed considerable effect sizes (odds ratio ~ 3.4 and 3.0, respectively) and support previously reported molecular biological findings.

Conclusion
Our approach detected novel specific genotype–phenotype relationships in BD that were missed by standard analyses like GWAS. While we developed and applied our method within the context of BD gene discovery, it may facilitate identifying highly specific genotype–phenotype relationships in subsets of genome-wide data sets of other complex phenotype with similar epidemiological properties and challenges to gene discovery efforts.
KW  - bipolar disorder
KW  - subphenotypes
KW  - rule discovery
KW  - data mining
KW  - genotype-phenotype patterns
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-220509
VL  - 6
ER  - 
TY  - JOUR
A1  - Bleilevens, Christian
A1  - Soppert, Josefin
A1  - Hoffmann, Adrian
A1  - Breuer, Thomas
A1  - Bernhagen, Jürgen
A1  - Martin, Lukas
A1  - Stiehler, Lara
A1  - Marx, Gernot
A1  - Dreher, Michael
A1  - Stoppe, Christian
A1  - Simon, Tim-Philipp
T1  - Macrophage migration inhibitory factor (MIF) plasma concentration in critically ill COVID-19 patients: a prospective observational study
JF  - Diagnostics
N2  - Mortality in critically ill coronavirus disease 2019 (COVID-19) patients is high and pharmacological treatment strategies remain limited. Early-stage predictive biomarkers are needed to identify patients with a high risk of severe clinical courses and to stratify treatment strategies. Macrophage migration inhibitory factor (MIF) was previously described as a potential predictor for the outcome of critically ill patients and for acute respiratory distress syndrome (ARDS), a hallmark of severe COVID-19 disease. This prospective observational study evaluates the predictive potential of MIF for the clinical outcome after severe COVID-19 infection. Plasma MIF concentrations were measured in 36 mechanically ventilated COVID-19 patients over three days after intensive care unit (ICU) admission. Increased compared to decreased MIF was significantly associated with aggravated organ function and a significantly lower 28-day survival (sequential organ failure assessment (SOFA) score; 8.2 ± 4.5 to 14.3 ± 3, p = 0.009 vs. 8.9 ± 1.9 to 12 ± 2, p = 0.296; survival: 56% vs. 93%; p = 0.003). Arterial hypertension was the predominant comorbidity in 85% of patients with increasing MIF concentrations (vs. decreasing MIF: 39%; p = 0.015). Without reaching significance, more patients with decreasing MIF were able to improve their ARDS status (p = 0.142). The identified association between an early MIF response, aggravation of organ function and 28-day survival may open future perspectives for biomarker-based diagnostic approaches for ICU management of COVID-19 patients.
KW  - Macrophage Migration Inhibitory Factor (MIF)
KW  - COVID-19
KW  - ICU treatment
KW  - acute respiratory distress syndrome (ARDS)
KW  - SOFA Score
KW  - Horowitz Quotient
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-228967
SN  - 2075-4418
VL  - 11
IS  - 2
ER  -